Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;15(6):1527-34.
doi: 10.1208/s12249-014-0177-9. Epub 2014 Jul 22.

Nanomedicine scale-up technologies: feasibilities and challenges

Rishi Paliwal  1 , R Jayachandra Babu, Srinath Palakurthi
Affiliations
Review

Nanomedicine scale-up technologies: feasibilities and challenges

Rishi Paliwal et al. AAPS PharmSciTech. 2014 Dec.

Abstract

Nanomedicine refers to biomedical and pharmaceutical applications of nanosized cargos of drugs/vaccine/DNA therapeutics including nanoparticles, nanoclusters, and nanospheres. Such particles have unique characteristics related to their size, surface, drug loading, and targeting potential. They are widely used to combat disease by controlled delivery of bioactive(s) or for diagnosis of life-threatening problems in their very early stage. The bioactive agent can be combined with a diagnostic agent in a nanodevice for theragnostic applications. However, the formulation scientist faces numerous challenges related to their development, scale-up feasibilities, regulatory aspects, and commercialization. This article reviews recent progress in the method of development of nanoparticles with a focus on polymeric and lipid nanoparticles, their scale-up techniques, and challenges in their commercialization.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic representation of material and process parameters, and regulatory aspects in the development of a nanomedicine
Fig. 2
Fig. 2
Scheme showing method of nanoparticle production as nanomedicine with various materials
Fig. 3
Fig. 3
Supercritical fluid technology for producing nanoparticles in which both the drug and the polymer (example: microcrystalline cellulose) are processed together to achieve nanoparticle stability and de-aggregation
See this image and copyright information in PMC

References

    1. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine. 2005;1:22–30. doi: 10.1016/j.nano.2004.11.009. - DOI - PubMed
    1. Ladj R, Bitar A, Eissa MM, Fessi H, Mugnier Y, Le Dantec R, et al. Polymer encapsulation of inorganic nanoparticles for biomedical applications. Int J Pharm. 2013;458(1):230–41. doi: 10.1016/j.ijpharm.2013.09.001. - DOI - PubMed
    1. Tang L, Cheng J. Nonporous silica nanoparticles for nanomedicine application. Nano Today. 2013;8:290–12. doi: 10.1016/j.nantod.2013.04.007. - DOI - PMC - PubMed
    1. Khan MS, Vishakante GD, Siddaramaiah H. Gold nanoparticles: a paradigm shift in biomedical applications. Adv Colloid Interface Sci. 2013;199–200:44–58. doi: 10.1016/j.cis.2013.06.003. - DOI - PubMed
    1. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649–59. doi: 10.1016/j.addr.2004.02.014. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources